TY - JOUR
T1 - Structural analysis of the interaction between spiroisoxazoline SMARt-420 and the Mycobacterium tuberculosis repressor EthR2
AU - Wohlkönig, Alexandre
AU - Remaut, Han
AU - Moune, Martin
AU - Tanina, Abdalkarim
AU - Meyer, Franck
AU - Desroses, Matthieu
AU - Steyaert, Jan
AU - Willand, Nicolas
AU - Baulard, Alain R
AU - Wintjens, René
N1 - Copyright © 2017 Elsevier Inc. All rights reserved.
PY - 2017/5/27
Y1 - 2017/5/27
N2 - Inhibition of transcriptional regulators of bacterial pathogens with the aim of reprogramming their metabolism to modify their antibiotic susceptibility constitutes a promising therapeutic strategy. One example is the bio-activation of the anti-tubercular pro-drug ethionamide, which activity could be enhanced by inhibiting the transcriptional repressor EthR. Recently, we discovered that inhibition of a second transcriptional repressor, EthR2, leads to the awakening of a new ethionamide bio-activation pathway. The x-ray structure of EthR2 was solved at 2.3 Å resolution in complex with a compound called SMARt-420 (Small Molecule Aborting Resistance). Detailed comparison and structural analysis revealed interesting insights for the upcoming structure-based design of EthR2 inhibitors as an alternative to revert ethionamide resistance in Mycobacterium tuberculosis.
AB - Inhibition of transcriptional regulators of bacterial pathogens with the aim of reprogramming their metabolism to modify their antibiotic susceptibility constitutes a promising therapeutic strategy. One example is the bio-activation of the anti-tubercular pro-drug ethionamide, which activity could be enhanced by inhibiting the transcriptional repressor EthR. Recently, we discovered that inhibition of a second transcriptional repressor, EthR2, leads to the awakening of a new ethionamide bio-activation pathway. The x-ray structure of EthR2 was solved at 2.3 Å resolution in complex with a compound called SMARt-420 (Small Molecule Aborting Resistance). Detailed comparison and structural analysis revealed interesting insights for the upcoming structure-based design of EthR2 inhibitors as an alternative to revert ethionamide resistance in Mycobacterium tuberculosis.
KW - Crystal structure
KW - Drug design
KW - Ethionamide
KW - Ligand-binding interaction
KW - TetR family
KW - Transcriptional repressor
KW - Models, Chemical
KW - Isoxazoles/chemistry
KW - Structure-Activity Relationship
KW - Protein Interaction Mapping
KW - Mycobacterium tuberculosis/metabolism
KW - Spiro Compounds/chemistry
KW - Repressor Proteins/chemistry
KW - Antitubercular Agents/chemistry
KW - Protein Binding
KW - Protein Conformation
KW - Bacterial Proteins/chemistry
KW - Molecular Docking Simulation
KW - Binding Sites
UR - http://www.scopus.com/inward/record.url?scp=85018561154&partnerID=8YFLogxK
U2 - 10.1016/j.bbrc.2017.04.074
DO - 10.1016/j.bbrc.2017.04.074
M3 - Article
C2 - 28416386
SN - 0006-291X
VL - 487
SP - 403
EP - 408
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
IS - 2
ER -